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ABSTRACT
The CYP2B1/cyclophosphamide (CPA) suicide gene therapy approach has been shown to be highly promis-
ing in clinical trials for the treatment of pancreatic cancer. However, delivering the therapeutic gene to a suf-
ficient number of tumor cells able to trigger a complete response remains a challenge. Target-specific deliv-
ery of adenovirus to fibroblast growth factor receptors (FGFRs) has been obtained in a variety of tumor
models and has been shown to highly increase transduction efficiency. In the present paper we have tested
the therapeutic outcome of retargeting the adenoviral vector, Ad-CYP2B1, to FGFRs, using an FGF2–Fab
conjugate, in pancreatic cancer models. First, we show a heterogeneous subcellular distribution of overex-
pressed FGFR-1 in pancreatic cancer cells. Higher transduction efficiency was observed in five of the six cell
lines studied after FGF2-AdGFPLuc infection. Interestingly, an association between FGFR-1 membrane cell
expression and viral entry was found. Moreover, tumors injected with FGF2-AdGFPLuc showed enhanced
and persistent transgene expression. Importantly, we demonstrate the relevant enhanced cytotoxic effect of
the FGF2-Ad-CYP2B1/CPA system in four of the six cell lines studied. Moreover, retargeting Ad-CYP2B1/CPA
to FGFRs resulted in a potent antitumoral effect and in an increased survival rate, in two human pancreatic
xenograft models. Thus, our results indicate that redirecting adenoviruses to FGFRs highly increases the po-
tency of the suicide system CYP2B1/CPA. Consequently, it may constitute a promising approach to the treat-




Bioactivation of the CYP2B1 gene by ifosfamide after local
injection of microencapsulated CYP2B1-producing cells has
shown promising results in the treatment of inoperable pan-
creatic carcinoma, suggesting that this system is a potent in-
ducer of cell death. In the present work we aimed to study
CYB2B1/cyclophosphamide (CPA) antitumoral activity
when delivered by a highly efficient gene transfer system
based on retargeting adenoviruses to fibroblast growth fac-
tor receptors (FGFRs). We showed that although there was
some degree of heterogeneity, pancreatic tumor cells highly
expressed FGFRs at the plasma membrane. Moreover, re-
targeting adenovirus to FGFRs enhanced adenoviral trans-
duction and increased CYP2B1/CPA cytotoxicity. Impor-
tantly, intratumoral delivery of the Ad-CYP2B1 through
FGFRs in combination with cyclophosphamide resulted in
a potent antitumoral effect and a significant increase in the
survival rate when assessed in two independent xenograft
models, indicating the efficient response of pancreatic tu-
mors to this type of therapy.
INTRODUCTION
PANCREATIC DUCTAL ADENOCARCINOMA remains a malig-nancy with no satisfactory treatment. Only in a few selected
cases does surgical resection offer the possibility of a cure.
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However, most patients are not eligible for this type of treat-
ment, and therefore undergo a variety of chemotherapeutic reg-
imens. Although an increase in the time free from recurrence
has been reported with such chemotherapies, there is no over-
all improvement in mean survival rate (Abrams, 2003).
Gene-directed enzyme prodrug therapy (GDEPT), which
uses cytochrome P-450 (CYP) enzymes to activate established
anticancer prodrugs, such as cyclophosphamide (CPA) and its
isomer ifosfamide, was first described to have antitumoral ac-
tivity in a brain tumor model (Wei et al., 1994, 1995). Inter-
estingly, it has also been shown to be a promising therapeutic
approach for pancreatic cancer both in mouse models and in
clinical studies (Lohr et al., 1998; Muller et al., 1999; Lohr et
al., 2001; Carrio et al., 2002). CPA and ifosfamide are alky-
lating prodrugs that covalently cross-link DNA in a cell cycle-
independent manner, triggering apoptotic cell death in the case
of CPA (Schwartz and Waxman, 2001), and either apoptosis or
necrosis in the case of ifosfamide (Karle et al., 2001; Schwartz
and Waxman, 2001). The efficacy of P-450 GDEPT has been
enhanced by highly diverse approaches, ranging from increas-
ing the bystander effect through expression of antiapoptotic fac-
tor p35 (Schwartz et al., 2002) to combination with several dif-
ferent strategies, such as with other suicide approaches (Aghi
et al., 1999; Carrio et al., 2002), with tumor suppressor genes
(Mercade et al., 2001), with viral oncolysis and chemosensiti-
zation (Chase et al., 1998; Tyminski et al., 2005), and with
replicating adenovirus that promotes the spreading of replica-
tion-defective Adeno-P450 (Jounaidi and Waxman, 2004). An-
other approach to increase the efficacy of CYP2B1/CPA treat-
ment has been the intratumoral injection of polymers
impregnated with CPA, resulting in an enhanced tumor con-
centration of active metabolites (Ichikawa et al., 2001).
Adenoviruses are attractive vectors for gene delivery and it
has been clearly established that entry of the most commonly
used adenoviral vector, serotype 5 (Ad5), into the cell starts by
interaction of the C-terminal knob viral fiber domain and the
primary cellular receptor, the coxsackievirus–adenovirus re-
ceptor (CAR). Although CAR is expressed on most normal ep-
ithelial cells, data suggest that CAR expression may be highly
variable in tumors, resulting in resistance to Ad5 infection (Li
et al., 1999; Anders et al., 2003). Consequently, modification
to redirect adenoviral tropism to receptors highly expressed in
cancer cells might improve tumor transduction, leading to an
increased antitumoral effect.
Fibroblast growth factor receptors (FGFRs) have already
been demonstrated to be overexpressed in human pancreatic
adenocarcinomas (Kobrin et al., 1993; Leung et al., 1994; Ohta
et al., 1995; Yamazaki et al., 1997). Retargeting adenovirus to
FGFRs through basic fibroblast growth factor-2 (FGF2) has
been shown to enhance cell transduction, both in vivo and in
vitro, in various tumor models (Sosnowski et al., 1996; Gold-
man et al., 1997; Rancourt et al., 1998; Gu et al., 1999; Wang
et al., 2005). In pancreatic cancer, it has been shown that tar-
geting AdTK/GCV (adenoviral vector carrying the herpes sim-
plex virus thymidine kinase gene/ganciclovir) enhances the cy-
totoxic effect of ganciclovir in vitro, although in only a limited
number of pancreatic cell lines (Kleeff et al., 2002).
In the present study our aim was to enhance CYP2B1/CPA
cytotoxic activity in pancreatic tumors by facilitating gene de-
livery. We report that targeting adenovirus to plasma membrane
fibroblast growth factor receptors enhances the efficiency of ad-
enovirus-mediated transduction of pancreatic tumor cells.
Moreover, increased expression that persists for a longer period
of time is achieved in vivo with the redirected virus. Interest-
ingly, we demonstrate that, by redirecting Ad-CYP2B1 to FGF
receptors, enhanced cytotoxic efficacy of the CYP2B1/CPA sui-
cide approach is obtained, both in cell culture and in vivo in
two independent human xenograft models.
MATERIALS AND METHODS
Cell lines and cell culture
Human pancreatic adenocarcinoma cell lines PANC-1 and
BxPC-3 were obtained from the American Type Culture Col-
lection (ATCC, Manassas, VA). The RWP-1 pancreatic cancer
cell line was kindly provided by F.X. Real (Institut Municipal
d’Investigació Mèdica, Barcelona, Spain) and NP-31, NP-9, and
NP-18 cells were derived from human pancreatic adenocarci-
noma biopsies and perpetuated as xenografts in nude mice (Vil-
lanueva et al., 1998). Cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (PANC-1, BxPC-3, RWP-1,
and NP-9) or in RPMI 1640 medium (NP-18 and NP-31), sup-
plemented with 10% fetal bovine serum (FBS) and antibiotics,
at 37°C in a humidified atmosphere containing 5% CO2.
Tissues
Thirty pancreatic ductal adenocarcinomas were studied. Sur-
gical specimens were obtained as formalin-fixed paraffin-em-
bedded tissues from patients undergoing surgical resection of
pancreatic adenocarcinoma from Hospital Universitari de Bell-
vitge (Barcelona, Spain) in the period between 1996 and 2001.
Characteristics of patients were as follows: age, 64 years (range,
40–95 years); sex, 18 male and 12 female; stage: T2, 1; T3, 27;
T4, 2; N0, 12; N1, 18; M, 28; M1, 2. All samples were col-
lected under institutional review board-approved protocols and
informed consent was obtained from each patient.
Immunofluorescence and confocal analysis
Cells were grown at a density of 3  105 cells per well and
fixed in 4% paraformaldehyde. The cells were then incubated
with rabbit anti-FGFR-1 polyclonal antibody (diluted 1:200;
Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C,
rinsed in phosphate-buffered saline (PBS)–0.3% Triton X-100,
and incubated for 1 hr with a goat anti-rabbit secondary anti-
body conjugated to Alexa 488 (diluted 1:400; Invitrogen Mo-
lecular Probes, Leiden, The Netherlands). The cells were
washed thoroughly and stained with TO-PRO-3 iodide (Invit-
rogen Molecular Probes, Eugene, OR) as a nuclear marker.
Immunofluorescent staining was analyzed with an inverted
Leica TCS SP2 confocal scanning laser microscope (Leica Mi-
crosystems, Wetzlar, Germany) and an HCX PL Apo 40/1.25
NA Oil Ph3 CS objective. Double immunofluorescence images
were acquired in a sequential mode, using the 488-nm line of
the argon laser (Alexa 488) and a 633-nm helium–neon laser
(TO-PRO-3 iodide). Images corresponding to six optical sec-
tions, with a sequential z step (depth of 1.06–1.10 m, de-
pending on the cell type) and an x/y resolution of 0.18 m, were
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captured from the lowest plane to the highest plane with Leica
Confocal Software (LCS; Leica Microsystems). Laser intensity
and detector sensitivity were set for the most intensely stained
sample, and all other pictures were captured with the same set-
tings. Omission of the primary antibody resulted in no signal.
Images were processed with Adobe Photoshop 6.0 software
(Adobe, San Jose, CA).
Immunohistochemistry
Formalin-fixed and paraffin-embedded samples were pre-
pared from human pancreatic adenocarcinoma tissues and from
xenografted tumors. Sections (5 m thick) were deparaffinized,
rehydrated, and treated with 10% normal goat serum. When
stated, the sections were incubated with either a rabbit anti-
FGFR-1 polyclonal antibody (diluted 1:200; Santa Cruz
Biotechnology) or a goat anti-rat CYP2B1 polyclonal antibody
(diluted 1:100; Daiichi Pure Chemicals, Tokyo, Japan), for 72
hr at 4°C. Bound antibodies were detected with universal bio-
tinylated secondary antibody and streptavidin–peroxidase com-
plex, in accordance with the supplier’s instructions (Universal
LSAB; Dako Diagnostics, Zug, Switzerland). Diaminobenzi-
dine was used as substrate. Sections were counterstained with
Mayer’s hematoxylin. All sections were examined with a Le-
ica DMR microscope (Leica Microsystems). Images were cap-
tured with a digital camera (Leica DC 500; Leica Microsys-
tems) and processed with Leica Image Manager (IM) and
Adobe Photoshop software. Omission of primary antibodies re-
sulted in the absence of any immunoreactivity.
Recombinant adenoviruses and 
FGF2-conjugated adenoviruses
Replication-defective adenovirus AdGFPLuc (Alemany and
Curiel, 2001), expressing green fluorescent protein (GFP) and
firefly luciferase (Luc) under the control of the cytomegalovirus
(CMV) promoter, was kindly provided by R. Alemany (Insti-
tut Català d’Oncologia, Barcelona, Spain). Ad-CYP2B1 has
been previously described (Mercade et al., 2001); it is an E1-
deleted Ad5 vector that expresses the rat cytochrome p4502B1
gene under the control of the CMV promoter. Recombinant ad-
enoviral vectors were propagated in the adenovirus-packaging
cell line HEK293 and purified by cesium chloride banding ac-
cording to standard techniques (Becker et al., 1994).
The FGF2–Fab molecule consists of a neutralizing mono-
clonal antibody directed against the Ad5 knob region and con-
jugated with a modified FGF2 as described (McDonald et al.,
1996; Sosnowski et al., 1996). To obtain FGF2-AdGFPLuc and
FGF2-Ad-CYP2B1 viruses, FGF2–Fab molecules were bound
to the corresponding adenovirus carrying either the GFPLuc
construct (AdGFPLuc) or the CYP2B1 gene (Ad-CYP2B1) at a
1:50 ratio (virus:FGF2–Fab).
In vitro transduction efficiency studies
To determine transduction efficiency, GFP expression was
visualized with an inverted Leica DM IRB fluorescence mi-
croscope, 72 hr postinfection. Images were captured with a Le-
ica DC 500 digital camera and processed with Leica IM and
Adobe Photoshop. To quantify transduction efficiency, cells
were lysed and assayed for luciferase activity according to the
manufacturer’s instructions (Luciferase Assay System; Promega,
Madison, WI). Luciferase activity was measured in an Orion
microplate luminometer (Berthold Detection Systems,
Pforzheim, Germany) and normalized to total protein levels.
Protein concentration was determined with a bicinchoninic acid
(BCA) protein assay kit (Pierce Biotechnology, Rockford, IL).
Dose–response analysis
Cell viability was measured and quantified in PANC-1,
BxPC-3, NP-31, NP-9, RWP-1, and NP-18 pancreatic cancer
cells by a colorimetric assay system based on the tretrazolium
salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT; Roche Molecular Biochemicals, Mannheim, Ger-
many), in accordance with the manufacturer’s instructions. Re-
sults were expressed as the percent absorbance determined in
treated wells relative to that in untreated wells. The 50% in-
fective dose (ID50) was defined as the multiplicity of infection
(MOI) resulting in 50% loss of cell viability relative to untreated
cells, and was estimated from the dose–response curves con-
structed from adenoviral MOIs by way of a standard nonlinear
model based on Hill’s equation.
In vivo bioluminescence
All animal experiments were approved by the Experimental
Animal Committee of the Autonomous Government of Catalo-
nia and performed in accordance with the recommendations for
the proper care and use of laboratory animals.
PANC-1 cells (2.5  106) were injected subcutaneously into
each posterior flank of BALB/c nude mice (Charles River
France, Lyon, France). Ten days after tumor implantation, the
tumors were divided into two groups (n  10 tumors per
group): one group received a single intratumoral injection of
AdGFPLuc at 2  108 PFU/tumor and the second group re-
ceived a single intratumoral injection of FGF2-AdGFPLuc at
2  108 PFU/tumor. On days 3 and 14 after adenoviral trans-
duction, luciferase activity was visualized and quantified with
an in vivo bioluminescence imaging system (IVIS; Xenogen/
Caliper Life Sciences, Alameda, CA). Images were captured
and analyzed with Living Image 2.20.1 software (Xenogen/
Caliper Life Sciences) overlaid on Igor Pro 4.06A software
(WaveMetrics, Lake Oswego, OR).
Briefly, the animals were anesthetized and the substrate fire-
fly D-luciferin (Xenogen/Caliper Life Sciences) was adminis-
tered intraperitoneally (16 mg/kg). Bioluminescent images were
acquired 12 min after substrate administration, after an initial
optimization study. For visualization purposes, a light image of
the animal was also taken and merged with the bioluminescent
image with the software overlay mode, permitting correlation
of the areas of luciferase expression with mouse anatomy. Lu-
ciferase activity within the tumor was quantified by measuring
the total amount of emitted light recorded by the charge-cou-
pled device (CCD) camera. The results are expressed as pho-
tons per second per square centimeter and per steradian.
Tumoral growth curves and survival studies
PANC-1 cells (2.5  106) or NP-31 cells (5  106) were in-
jected subcutaneously into BALB/c nude mice (Charles River
France). The tumors were allowed to grow, and treatment was
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initiated when the tumors reached a mean volume of 70 mm3.
The tumors were randomized into five groups: group 1 received
saline solution intratumorally and CPA intraperitoneally; group
2 received Ad-CYP2B1; group 3 received FGF2-Ad-CYP2B1;
group 4 was treated with Ad-CYP2B1 plus CPA; and group 5
was treated with FGF2-Ad-CYP2B1 plus CPA. Considering the
different kinetics in tumor growth between PANC-1 and NP-
31 xenografts, two treatment protocols were applied. In all
cases, three intratumoral injections of 2  108 PFU of the re-
spective recombinant adenovirus (Ad-CYP2B1 or FGF2-Ad-
CYP2B1) were administered on days 11, 13, and 17 after tu-
mor implantation (PANC-1 xenografts) or on days 9, 14, and
19 after tumor implantation (NP-31 xenografts). Moreover,
groups 1, 4, and 5 received four intraperitoneal injections of
CPA (100 mg/kg) on days 12, 14, 21, and 27 after tumor im-
plantation (PANC-1 xenografts) or on days 10, 15, 20, and 29
after tumor implantation (NP-31 xenografts). Detailed admin-
istration protocols are shown in Fig. 5 (see below). Tumor vol-
ume was measured every other day and was calculated ac-
cording to the following formula: V (mm3)  [larger diameter
(mm)  smaller diameter2 (mm2)]/2. Survival comparisons
were displayed by means of Kaplan–Meier curves, and treated
groups were compared by log-rank test.
Statistical analysis
Descriptive statistical analysis was performed with SYSTAT
(SPSS, Chicago, IL). Results are expressed as means  SEM.
The Mann–Whitney nonparametric test was used for statis-
tical analysis (two-tailed) of the in vitro and in vivo transduc-
tion efficiency studies. p  0.05 was taken as the level of sig-
nificance.
ID50 values were estimated from the dose–response curves,
using a nonlinear model. Confidence intervals were computed
by bootstrap techniques (Venables, 2002). Comparison between
FGF2-Ad-CYP2B1 and Ad-CYP2B1 was performed with a per-
mutation test (Good, 1994). p  0.05 was considered statisti-
cally significant.
The in vivo tumor growth and survival analyses were per-
formed with S-PLUS functions. In tumor growth analyses,
mice, repeated measures, and tumor location in the mouse are
considered nested classification factors. We associate random-
effect terms with the animal factor, the day of measurement,
and the site nested in the animal. Hence, general linear-mixed
models (Heitjan et al., 1993) are used to estimate the effects of
treatment on tumor growth by taking nested and repeated de-
sign into account (Pinheiro and Bates, 2000). These models al-
lowed us to make an analysis of the overall effect, and of the
effect of each treatment. Estimation of coefficients, and their
associated p values, was based on restricted maximum likeli-
hood. A plot of residual versus fitted values was used to check
the assumptions of the model. Variance function structure was
used to model the heterocedasticity of the day-to-day errors.
p  0.05 (Bonferroni correction) was considered statistically
significant after performing multiple comparisons among
treated groups. Survival analyses were performed to analyze
time-to-event probability. We define an event as the time at
which an animal’s tumor reached a preset threshold volume.
We set two different scenarios: 200 mm3 (PANC-1 tumors) and
400 mm3 (NP-31 tumors). The survival curves obtained with
the different treatments were compared, and animals whose tu-
mor size never reached the threshold were included as right-
censored information. The log-rank test was used to determine
the statistical significance of differences in time-to-event 
(Therneau and Grambsch, 2000). p  0.05 was considered sta-
tistically significant.
RESULTS
Heterogeneous subcellular localization of FGFR-1 in
pancreatic cancer cells
To explore the feasibility of retargeting adenovirus to FGFRs
in pancreatic tumors we first determined the expression and cel-
lular localization of FGFR-1 in a panel of six pancreatic can-
cer cell lines by confocal immunofluorescence microscopy (Fig.
1A). We produced a series of six optical sections to more pre-
cisely assess the subcellular localization of FGFR-1. Im-
munostaining revealed a heterogeneous pattern of FGFR-1 dis-
tribution among the different cell lines. PANC-1, NP-31, and
RWP-1 displayed moderate cytoplasmic and nuclear staining,
but a strong membranous signal. BxPC-3 and NP-9 exhibited
a mild signal in all compartments. Interestingly, high-level
staining was observed in the nucleolus of BxPC-3. On the other
hand, NP-18 cells showed weak cytoplasmic and membranous
staining but strong perinuclear immunoreactivity.
We also confirmed the expression of FGFR-1 in a series of
30 pancreatic ductal adenocarcinomas. Twenty-nine of 30 tu-
mor samples (97%) showed positive immunostaining against
FGFR-1 in neoplastic ducts, with intense signal detected in 16
of them (Fig. 1B, panel a). Detailed analysis of FGFR-1 ex-
pression showed a heterogeneous distribution inter- and intra-
tumorally, with positive signal in the membrane that ranged
from strong to weak and abundant immunoreactivity in the cy-
toplasm of neoplastic cells (Fig. 1B, panel b).
Targeting adenovirus to FGF receptors results in
enhanced and persistent transgene expression in
pancreatic tumors
We next studied the effects of FGF2-retargeted adenoviruses
on transduction efficiency and transgene expression in pancre-
atic cancer cells. PANC-1, BxPC-3, NP-31, NP-9, RWP-1, and
NP-18 cells were transduced with 100 MOI of AdGFPLuc or
FGF2-AdGFPLuc and, 3 days later, GFP-positive cells were vi-
sualized under a fluorescence microscope and luciferase activ-
ity was measured. A remarkable increase in GFP-positive cells
was detected in PANC-1, BxPC-3, NP-31, and NP-9 cells trans-
duced with the retargeted adenovirus, whereas no difference be-
tween the two viruses was observed in RWP-1 cells, and a re-
duced number of GFP-positive cells was found in NP-18 cells
transduced with FGF2-AdGFPLuc (Fig. 2A). Next, we quanti-
fied transgene expression by measuring luciferase activity in the
transduced cells. In PANC-1, BxPC-3, NP-31, and NP-9 cells
the levels of luciferase activity achieved with the FGF2-AdGFP-
Luc adenovirus ranged from 10- to 100-fold higher than those
achieved with the unmodified vector. However, similar levels
were detected in RWP-1 cells with both viruses and a 6.6-fold
decrease in luciferase activity was detected in NP-18 cells trans-
duced with the redirected virus (Fig. 2B). In PANC-1, BxPC-3,
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FIG. 1. FGFR-1 expression in pancreatic cancer cells and in human pancreatic cancer. (A) Confocal immunofluorescence mi-
croscopy analysis of pancreatic cancer cell lines PANC-1, BxPC-3, NP-31, NP-9, RWP-1, and NP-18, using a rabbit anti-FGFR-1
polyclonal antibody. Cells exhibited intense membranous and cytoplasmic FGFR-1 signal (arrows). Intense perinuclear staining was
observed in NP-18 cells and in the nucleolus of BxPC-3 cells (arrowheads). Nuclei were stained with TO-PRO-3 iodide (blue). Scale
bar: 20 m. The images are representative of samples from at least three independent experiments. (B) Immunohistochemistry anal-
ysis of FGFR-1 expression in human pancreatic cancer tissues revealed membrane and cytoplasmic staining located in the neoplas-
tic ducts (arrows) (panel a). At higher magnifications, areas of strong (arrows) to weak (arrowheads) membrane-positive staining
were observed (panel b). Scale bars: panel a, 200 m; panel b, 100 m.
NP-31, RWP-1, and NP-18 cells lines a correlation between lu-
ciferase activity and GFP was observed. However, in NP-9 cells
high levels of luciferase expression were detected with the
FGF2-retargeted virus although only a moderate increase in
GFP-positive cells was observed.
We next investigated the efficiency of retargeting adeno-
virus to FGFRs in PANC-1 tumor-bearing mice. First, we
confirmed that PANC-1 cells, when grown as xenografts,
would still maintain the expression of FGFR-1. Positive
FGFR-1 immunostaining was detected in ductlike cancer
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FIG. 2. Evaluation of FGF2-AdGFPLuc and AdGFPLuc transduction efficiency in vitro, in pancreatic cancer cells. Cells (20,000)
were plated in triplicate in 96-well plates. GFP and firefly luciferase expression were determined from the same cell cultures 72
hr after AdGFPLuc or FGF2-AdGFPLuc transduction (MOI of 100). (A) GFP was visualized in live cells by phase-contrast flu-
orescence microscopy. Scale bar: 200 m. (B) Luciferase expression was quantified and normalized to total protein levels. Re-
sults are expressed as light units per microgram protein. Values are represented as means  SEM of three independent experi-
ments. ***p  0.0001.
cells (Fig. 3A). To compare the in vivo transduction effi-
ciency of FGF2-retargeted adenovirus with that of nonretar-
geted adenovirus, PANC-1 xenografts received a single dose
of 2  108 PFU of FGF2-AdGFPLuc or AdGFPLuc and, 3
and 14 days later, luciferase activity was monitored by bio-
luminescence imaging. No bioluminescence was detected
above background levels in mock-infected mice before D-lu-
ciferin administration. Bioluminescence images of represen-
tative animals transduced with FGF2-AdGFPLuc or AdGFP-
Luc are each displayed as a pseudocolor image overlaid on
a gray-scale image of the whole mouse (Fig. 3B). Serial im-
ages were obtained from all animals and the mean photon
flux relative to peak signal was determined (Fig. 3C). An in-
tense signal was observed in all tumors on day 3 after ade-
noviral transduction. Importantly, a statistically significant
increase in luciferase expression (6.2-fold, p  0.005) was
detected in tumors that received the FGF2-redirected virus.
Moreover, on day 14 after viral administration luciferase ac-
tivity was still detected in tumors that received the FGF2-
AdGFPLuc virus, whereas no light was detected from tumors
injected with the nonredirected virus. These results clearly
show increased expression of the transgene after in vivo
FGF2-adenovirus retargeting.
Targeting Ad-CYP2B1 to FGFRs increases
CYP2B1/CPA cytotoxicity in vitro
To study the consequences of redirecting the CYP2B1/CPA
system to FGFRs in pancreatic tumors, six different pancre-
atic cancer cell lines, expressing variable membrane levels of
FGFR-1, were mock-infected or transduced either with Ad-
CYP2B1 or FGF2-Ad-CYP2B1 at various viral doses. Four
hours after transduction, the cells were treated with cy-
clophosphamide (CPA) for 4 days and cell viability was then
assessed by MTT assay. Dose–response curves were obtained
(Fig. 4A) and MOIs corresponding to the ID50 values were
determined (Fig. 4B). Statistically significant differences in
cytotoxicity between FGF2-Ad-CYP2B1 and Ad-CYP2B1
were observed in the various cell lines studied (p  0.0001).
An enhanced cytotoxic effect was obtained with the FGF2-
Ad-CYP2B1/CPA system in PANC-1 (4.6-fold), BxPC-3 (5.0-
fold), NP-9 (9.4-fold), and NP-31 (11.6-fold) cells. No dif-
ferences were observed in RWP-1 cells, whereas a 3-fold
reduction in cytotoxicity was detected in NP-18 cells treated
with the redirected system. These results indicate that
CYP2B1/CPA sensitivity can be highly increased by favoring
vector transduction efficiency.
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FIG. 3. In vivo bioluminescence studies. Comparative analysis of FGF2-AdGFPLuc and AdGFPLuc luciferase expression in
vivo. (A) FGFR-1 immunohistochemical analysis in PANC-1 xenografts. An FGFR-1-positive signal was detected in the mem-
brane and cytoplasm of ductlike cancer cells (arrow). Scale bar: 30 m. (B and C) Randomized tumors were injected intratu-
morally with a single dose of 2  108 PFU of AdGFPLuc (n  10) or FGF2-AdGFPLuc (n  10). (B) Representative biolumi-
nescence emission images of mice receiving AdGFPLuc (left) or FGF2-AdGFPLuc (right); images taken on day 3 (top) and day
14 (bottom). To minimize possible differences between groups, luminescent images were acquired with the same binning options
and integration times. Luciferase activity is color coded with red, indicating the highest amount of emitted light (2 million pho-
tons/sec), and blue, indicating the lowest (500,000 photons/sec). (C) Quantification of luciferase expression in vivo on days 3
and 14. Luciferase activity recorded from the tumors was quantified by measuring the total amount of emitted light captured by
the camera. Results are expressed as photons per second per square centimeter and per steradian. Significant differences were




FIG. 4. Dose–response curves of pancreatic cancer cells transduced with Ad-CYP2B1 or FGF2-Ad-CYP2B1 and treated with CPA.
Cells (5  103 per well) were seeded in triplicate and infected with a dose range of 0 to 10,000 MOI of Ad-CYP2B1 or FGF2-
Ad-CYP2B1. Four hours later 0.5 mM CPA was added to the culture. Cell viability was measured after 4 days of treatment. Mock-
infected cultures receiving 0.5 mM CPA were considered 100% viable. (A) PANC-1, BxPC-3, NP-31, NP-9, RWP-1, and NP-18
dose–response curves. Curve values are plotted as means  SEM of three independent experiments. Open circles, FGF2-Ad-
CYP2B1/CPA; solid circles, Ad-CYP2B1/CPA. (B) ID50 values, 95% confidence interval (95% CI), and p values were obtained
from at least three independent experiments.
Targeting Ad-CYP2B1/CPA to FGF receptors leads to
increased antitumoral effect in PANC-1 and NP-31
xenografts
We next examined the ability of Ad-CYP2B1 or FGF2-Ad-
CYP2B1, in combination with CPA, to inhibit tumor growth in
vivo. PANC-1 and NP-31 xenografts were established in nude
mice. Tumorigenic potential is governed by complex processes
and has many requirements (Hanahan and Weinberg, 2000).
The expansion of solid tumors has particular characteristics for
any given tumor model. As can be observed in Fig. 5, the tu-
mor growth kinetics of PANC-1 and NP-31 are quite different:
PANC-1 tumors grow much more rapidly than NP-31 tumors.
Bearing this in mind, we decided to apply a slightly different
treatment schedule for each tumor model.
PANC-1 tumors received Ad-CYP2B1 or FGF2-Ad-CYP2B1
at a viral dose of 6  108 PFU/tumor, distributed in two intra-
tumoral injections spaced by 1 day, and a third injection 4 days
later. When stated, the mice received CPA at 100 mg/kg 24 hr
after the first two viral injections. Four days after the last viral
injection, mice received a third dose of CPA that was repeated
6 days later. As shown in Fig. 5A, the three control groups
(mice treated with CPA and mice injected with Ad-CYP2B1 or
FGF2-Ad-CYP2B1 and not receiving CPA) showed continuous
and stable growth. However, CPA treatment slightly inhibited
PANC-1 tumor growth, consistent with liver P-450 CPA me-
tabolization. Regarding the two virus/CPA-treated groups, the
mice receiving FGF2-Ad-CYP2B1 plus CPA showed the most
dramatic response (p  0.0001). Sustained regression in tumor
volume began on day 12, after the first CPA injection, leading
to an increase in median survival time, as observed in the 
Kaplan–Meier curve. Tumors injected with Ad-CYP2B1 and
treated with CPA showed an inhibition of tumor growth that
was statistically significant when compared with the control
group, which received virus but not CPA (p  0.0005). Both
treatments, FGF2-Ad-CYP2B1 plus CPA and Ad-CYP2B1 plus
CPA, induced a reduction in tumor progression that was sta-
tistically significant when compared with the CPA group (p 
0.0071 and p  0.0459, respectively). Importantly, it was on
day 19, once the total viral dose had been administered, when
statistically significant differences in tumor growth between the
two treated groups were first observed (p  0.05). Moreover,
a statistically significant difference in median survival rate be-
tween the two treated groups was also observed (log-rank test:
0.0444) (Fig. 5A).
NP-31 tumors received Ad-CYP2B1 or FGF2-Ad-CYP2B1
at a viral dose of 6  108 PFU/tumor, distributed in three in-
tratumoral injections spaced by 5 days each. When stated, the
mice received CPA at 100 mg/kg 24 hr after each viral injec-
tion. Ten days after the last viral injection, the mice received
an additional dose of CPA. As shown in Fig. 5B, the three con-
trol groups (CPA, Ad-CYP2B1, and FGF2-Ad-CYP2B1)
showed continuous and stable growth. Again, as in PANC-1
xenografts, the mice receiving FGF2-Ad-CYP2B1 plus CPA ex-
hibited the most dramatic response (p  0.0073). Maximum re-
gression in tumor volume was observed on day 21, after the ad-
ministration of all three viral doses. As shown in the
Kaplan–Meier curves, a 2-fold increase in the median survival
time was observed in animals treated with FGF2-Ad-CYP2B1
plus CPA, as compared with the three control groups. Mice
treated with Ad-CYP2B1 plus CPA showed a slow progression
in tumor growth that was significantly different on days 21 and
24 and at the end of the experiment, when compared with the
group that received the virus but not CPA. Importantly, on day
15, after the first virus/CPA treatment, statistically significant
differences in tumor growth between the two treated groups
were observed (p  0.05). Moreover, a statistically significant
difference in median survival rate between the two treated
groups was also found (log-rank test: 0.01) (Fig. 5B).
In an attempt to gain insight concerning the enhanced anti-
tumoral effect achieved with the FGF2-retargeted adenovirus,
we decided to investigate CYP2B1 expression in tumors in-
jected with redirected or nonredirected virus. PANC-1 and 
NP-31 tumors were injected with Ad-CYP2B1 or FGF2-Ad-
CYP2B1 at 2  108 PFU/tumor, and 3 days later tumors were
excised and analyzed for CYP2B1 expression by immunohis-
tochemistry. PANC-1 and NP-31 xenografts injected with ei-
ther virus showed positive staining for CYP2B1. Interestingly,
tumors injected with FGF2-Ad-CYP2B1 expressed CYP2B1
protein in a greater number of cells, suggesting that the FGF2-
directed virus was reaching a larger area of the tumor mass (Fig.
6A and B). Moreover, with the FGF2-directed virus, increased
CYP2B1 signal was detected in the cytoplasm, indicating most
probably that a higher number of viral particles had entered per
cell (Fig. 6A, inset).
DISCUSSION
The bioactivation of cyclophosphamide or ifosfamide by P-
450 enzymes has been shown to trigger antitumoral responses,
both in preclinical and clinical studies, proving the therapeutic
potential of this approach for pancreatic cancer therapy (Lohr
et al., 2001).
Many different approaches have been addressed to optimize
P-450 efficacy, from increasing the catalytic activity of the P-
450 transgene with the P-450 reductase gene (Chen et al., 1997)
to attempting to overcome the inability of current gene therapy
vectors to achieve gene transduction over a significant tumor
area. Along these lines, it is important to note that, in her-
pesvirus type 1-infected tumors, cyclophosphamide itself has
been reported to act as a facilitator of viral survival and prop-
agation within the tumors (Ikeda et al., 1999, 2000). In addi-
tion, strategies based on amplifying the bystander cytotoxic ef-
fect of P-450-expressing tumor cells (Schwartz et al., 2002), as
well as strategies based on using conditionally replicative
viruses (Jounaidi and Waxman, 2004; Tyminski et al., 2005),
have been tested.
The present study shows that it is possible to enhance
CYP2B1/CPA antitumoral activity in pancreatic tumor models
by retargeting adenoviral vectors expressing the CYP2B1 gene
to FGF receptors. This approach is based on the use of a con-
jugate protein composed of the FGF2 ligand linked to the Fab
fragment of the anti-adenoviral knob antibody. This targeting
system has previously been shown to enhance adenoviral trans-
duction of cells that express high-affinity FGF receptors (Gold-
man et al., 1997; Rancourt et al., 1998; Wang et al., 2005).
Several studies have also shown that pancreatic tumor cells and
pancreatic adenocarcinoma overexpress FGFRs (Kobrin et al.,
1993; Leung et al., 1994; Kleeff et al., 2002; Tyminski et al.,
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FIG. 5. Tumoral growth and Kaplan–Meier survival curves of two pancreatic cancer xenograft models treated with Ad-CYP2B1
or FGF2-Ad-CYP2B1 plus CPA. (A) Animals bearing PANC-1 xenografts were randomized to five groups: three control groups:
CPA (n  6 tumors), Ad-CYP2B1 (n  6 tumors), and FGF2-Ad-CYP2B1 (n  8 tumors) and two treated groups: Ad-CYP2B1
plus CPA (n  9 tumors) and FGF2-Ad-CYP2B1 plus CPA (n  9 tumors). Three intratumoral injections of Ad-CYP2B1 or
FGF2-Ad-CYP2B1 (2  108 PFU/dose) and four intraperitoneal injections of CPA (100 mg/kg per dose) were administered ac-
cording to the protocol indicated. (B) Mice bearing NP-31 tumors were randomized into three control groups: CPA (n  8 tu-
mors), Ad-CYP2B1 (n  6 tumors), and FGF2-Ad-CYP2B1 (n  8 tumors) and two treated groups: Ad-CYP2B1 plus CPA (n 
8 tumors) and FGF2-Ad-CYP2B1 plus CPA (n  8 tumors). Three intratumoral injections of Ad-CYP2B1 or FGF2-Ad-CYP2B1
(2  108 PFU/dose) and four intraperitoneal injections of CPA (100 mg/kg per dose) were administered according to the proto-
col indicated. Tumor growth curves (left) and Kaplan–Meier survival curves (right) are plotted. Comparisons of overall growth
curves are described in Results. Significance, *p  0.05, refers to a comparison of the two treated groups (Ad-CYP2B1 plus CPA
and FGF2-Ad-CYP2B1 plus CPA) at each time point studied. Survival curves were compared by log-rank test. A significant in-
crease in survival was achieved in animals treated with FGF2-Ad-CYP2B1 plus CPA versus animals treated with Ad-CYP2B1
plus CPA (log-rank test  0.04, PANC-1; log-rank test  0.01, NP-31).
FIG. 6. CYP2B1 expression in pancreatic cancer tumors injected with Ad-CYP2B1 or FGF2-Ad-CYP2B1. Tumors were in-
jected with a single dose (2  108 PFU/tumor) of Ad-CYP2B1 (left) or FGF2-Ad-CYP2B1 (right). Three days later the tumors
were excised and CYP2B1 expression was analyzed by immunohistochemistry. (A) PANC-1 (top) and NP-31 (bottom): Stronger
positive staining was detected in tumors injected with FGF2-Ad-CYP2B1. Scale bars: 50 m. Higher magnifications (insets) re-
veal CYP2B1 expression in the cytoplasm of tumoral cells (arrows). Scale bar: 10 m. (B) PANC-1: An increased number of
positive cells was detected in tumors injected with FGF2-Ad-CYP2B1. Scale bar: 20 m.
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2005). However, what is demonstrated here is that for the re-
targeting approach to work efficiently it is important not only
to know that there is FGFR expression but also, and more rel-
evantly, to precisely define FGFR localization in the tumor. Our
data show that FGFR-1 is overexpressed and highly heteroge-
neously distributed in pancreatic tumor cells, with a membrane
localization that ranges from a strong to a weak signal, de-
pending on the cell line. This uneven localization pattern of
FGFR-1 in the ductal cancer cells was also present in tumor
samples. The variable expression of FGF receptors in the
plasma membrane of tumor cell lines was not restricted to
FGFR-1; it also extended to the other family receptors
(FGFR1–4; data not shown).
One could argue that endogenous FGF2 production could
compete with FGF2-adenoviruses for binding to FGFRs,
thereby limiting their transduction capability. However, this
would not be an issue because endogenous FGF2 would not be
biologically available to bind to FGFRs (Ornitz and Itoh, 2001).
We observed that PANC-1, NP-31, and RWP-1 cells, all hav-
ing a strong FGFR-1 membrane signal, showed a high number
of GFP-positive cells after FGF2-AdGFPLuc transduction,
whereas NP-9 and BxPC-3 cells, with moderate membrane sig-
nal, and NP-18 cells, with a weak membrane signal, showed
fewer GFP-positive cells. Thus, these results indicate an asso-
ciation between membrane FGFR localization and GFP ex-
pression when FGF2-adenovirus is used.
Interestingly, infection with the retargeted adenovirus re-
sulted in increased GFP expression and enhanced luciferase ac-
tivity in four of the six cell lines studied, as compared with the
nonretargeted virus, whereas no differences were observed in
RWP-1 cells, and a lower level of expression was observed in
NP-18 cells. The fact that NP-18 cells presented higher trans-
duction efficiency with the nonredirected virus would be in
agreement with the elevated CAR levels (our unpublished data)
and the weak FGFR membrane signal observed. However, we
identified elevated luciferase expression in NP-9 cells, but a
moderate increase in GFP-positive cells. These results are in
line with previous observations that had reported enhanced
transgene expression, independent of viral entry, suggesting the
involvement of other cell mechanisms in FGF2 retargeting
(Doukas et al., 1999; Hoganson et al., 2001).
Targeting the CYP2B1/CPA system to FGFRs resulted in a
relevant cytotoxic effect in PANC-1, BxPC-3, NP-9, and NP-
31 cells that was 4.6-, 5.0-, 9.4-, and 11.6-fold stronger (re-
spectively) than that achieved with the nonredirected system,
whereas similar effects were observed in RWP-1 cells and a re-
duced response was obtained in NP-18 cells. These results cor-
relate with the transduction efficiency data, thus indicating that
the differences in CYP2B1/CPA cytotoxicity could be the con-
sequence of both an increase in viral entry and the enhance-
ment of transgene expression. Interestingly, these findings
showed that cells that were apparently resistant to
CYP2B1/CPA treatment might be sensitized if infected with
FGF2-Ad-CYP2B1, targeting the FGF receptors, and treated
with CPA. Similar observations were made by Kleeff et al.,
who redirected the TK/GCV system to FGFRs, although the ef-
fect was not that strong and was observed in only two of the
six cell lines studied (Kleeff et al., 2002). A common cell line,
PANC-1, was used in both studies and the application of the
two treatments, FGF2-AdTK/GCV and FGF2-Ad-
CYP2B1/CPA, had completely different outcomes. Whereas re-
sistance to GCV was reported by Kleeff et al., we observed a
clear increase in CPA sensitivity. The apparent discrepancy may
be explained by the ability of this particular cell line to respond
to TK/GCV or CYP2B1/CPA cytotoxic therapies.
Interestingly, in vivo PANC-1 tumors, as was found with NP-
31 tumors, showed a greater response when treated with the redi-
rected virus FGF2-Ad-CYP2B1 and CPA. A statistically signif-
icant reduction in tumor volume and a significant increase in
survival were clearly appreciated. Several factors may have con-
tributed to the success of these treatments: for example, the op-
timization of the CYP2B1/CPA administration protocols, on the
basis of PANC-1 or NP-31 tumor behavior, plus the use of a re-
peated CPA dosing schedule and retreatment, as opposed to a
single bolus or continuous drug exposure (Browder et al., 2000;
Schwartz et al., 2002; Jounaidi and Waxman, 2004; Tyminski et
al., 2005). Moreover, the increased persistence of the protein in
the tumor, observed in the bioluminescence studies, may have
also facilitated the response to CPA readministrations. Further-
more, the increased efficacy of redirected FGF2-Ad-
CYP2B1/CPA could also be explained by the data we obtained
from our analysis of CYP2B1 expression in tumors. An increase
in the number of CYP2B1-expressing cells plus the enhanced ex-
pression per cell, would appear to suggest that the redirected virus
was able to reach an extended tumor area and that probably a
greater number of viral particles would have entered each cell.
These results suggest that with this retargeting system the intra-
tumoral injection limitations, which have been associated with
adenovirus, because of viral particle retention at the site of in-
jection (Vile et al., 2002), might be partially overcome.
In summary, the present report demonstrates for the first time
an enhanced antitumoral response in vitro and in vivo by FGF2-
redirected adenovirus in pancreatic cancer models, and suggests
that retargeting the suicide CYP2B1/CPA system to FGFRs
could be of clinical use for a subgroup of pancreatic cancer pa-
tients, with tumors that precisely overexpress FGF receptors at
high density in the cell membrane.
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